RT Journal Article
SR Electronic
T1 Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.08.21259776
DO 10.1101/2021.07.08.21259776
A1 Tenforde, Mark W.
A1 Patel, Manish M.
A1 Ginde, Adit A.
A1 Douin, David J.
A1 Talbot, H. Keipp
A1 Casey, Jonathan D.
A1 Mohr, Nicholas M.
A1 Zepeski, Anne
A1 Gaglani, Manjusha
A1 McNeal, Tresa
A1 Ghamande, Shekhar
A1 Shapiro, Nathan I.
A1 Gibbs, Kevin W.
A1 Files, D. Clark
A1 Hager, David N.
A1 Shehu, Arber
A1 Prekker, Matthew E.
A1 Erickson, Heidi L.
A1 Exline, Matthew C.
A1 Gong, Michelle N.
A1 Mohamed, Amira
A1 Henning, Daniel J.
A1 Steingrub, Jay S.
A1 Peltan, Ithan D.
A1 Brown, Samuel M.
A1 Martin, Emily T.
A1 Monto, Arnold S.
A1 Khan, Akram
A1 Hough, C. Terri
A1 Busse, Laurence
A1 ten Lohuis, Caitlin C.
A1 Duggal, Abhijit
A1 Wilson, Jennifer G.
A1 Gordon, Alexandra June
A1 Qadir, Nida
A1 Chang, Steven Y.
A1 Mallow, Christopher
A1 Gershengorn, Hayley B.
A1 Babcock, Hilary M.
A1 Kwon, Jennie H.
A1 Halasa, Natasha
A1 Chappell, James D.
A1 Lauring, Adam S.
A1 Grijalva, Carlos G.
A1 Rice, Todd W.
A1 Jones, Ian D.
A1 Stubblefield, William B.
A1 Baughman, Adrienne
A1 Womack, Kelsey N.
A1 Lindsell, Christopher J.
A1 Hart, Kimberly W.
A1 Zhu, Yuwei
A1 Olson, Samantha M.
A1 Stephenson, Meagan
A1 Schrag, Stephanie J.
A1 Kobayashi, Miwako
A1 Verani, Jennifer R.
A1 Self, Wesley H.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/07/08/2021.07.08.21259776.abstract
AB Background As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes.Methods In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid-19 and hospital-based controls who tested negative for SARS-CoV-2.Results Among 1210 participants, median age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine doses ≥14 days before illness onset) had been received by 45/590 (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49 years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%) than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%).Conclusion During March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing Covid-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population.Competing Interest StatementPotential Conflicts of Interest: Vaccine manufacturers had no role in the conduct, analysis, or dissemination of this work. The primary funder for this work was the US Centers for Disease Control and Prevention (CDC); CDC scientists participated in this work and are included as authors. The following potential conflicts of interest have been reported by the authors. Dr. Brown reports grants from CDC during the conduct of the study; personal fees from Hamilton, other from Faron, other from Sedana, grants from Janssen, grants from NIH, grants from DoD, other from Oxford University, other from Brigham Young University, outside the submitted work. Dr. Casey reports grants from National Institute of Health, outside the submitted work. Dr. Chang was a speaker for La Jolla Pharmaceuticals in 2018, and consulted for PureTech Health in 2020. Dr. Chappell reports grants from CDC, grants from NCATS/NIH during the conduct of the study. Dr. Exline reports other from Abbott Labs, outside the submitted work. Dr. Files reports personal fees as consultant from Cytovale, DSMB member from Medpace, outside the submitted work. Dr. Gaglani reports grants from CDC-Vanderbilt, during the conduct of the study; grants from CDC, grants from CDC, grants from CDC-Abt, grants from CDC-Westat, outside the submitted work. Dr. Gershengorn reports personal fees from Gilead Sciences, Inc, outside the submitted work. Dr. Ginde reports grants from CDC, during the conduct of the study; grants from AbbVie, grants from Faron Pharmaceuticals, outside the submitted work. Dr. Gong reports grants from CDC, during the conduct of the study; grants from NIH, grants from AHRQ, other from Regeneron, personal fees from Philips Healthcare, outside the submitted work. Dr. Grijalva reports other from Pfizer, other from Merck, other from Sanofi-Pasteur, grants from Campbell Alliance/Syneos Health, grants from Centers for Disease Control and Prevention, grants from National Institutes of Health, grants from Food and Drug Administration, grants from Agency for Health Care Research and Quality, grants from Sanofi, outside the submitted work. Dr. Hager reports other from CDC via subcontract with Vanderbilt during the conduct of the study; other from Incyte Corporation, other from Marcus Foundation, other from EMPACT Precision Medicine via VUMC, outside the submitted work. Dr. Halasa reports grants from CDC during the conduct of the study; grants and non-financial support from Sanofi, grants from Quidel outside the submitted work. Dr. Khan reports grants from United Therapeutics, grants from Johnson & Johnson, grants from 4D Medical, grants from Lung LLC, grants from Reata Pharmaceuticals, outside the submitted work. Dr. Kwon reports grants from CDC, during the conduct of the study. Dr. Lauring reports personal fees from Sanofi, personal fees from Roche, outside the submitted work. Dr. Lindsell reports grants from CDC, during the conduct of the study; grants from NIH, grants from DoD, grants from Marcus Foundation, other from bioMerieux, other from Endpoint LLC, other from Entegrion Inc, outside the submitted work; in addition, Dr. Lindsell has a patent for risk stratification in sepsis and septic shock issued. Dr. Martin reports grants from Vanderbilt University / Centers for Disease Control and Prevention, during the conduct of the study; personal fees from Pfizer, grants from Merck, outside the submitted work. Dr Monto reports consulting fees from Sanofi-Pasteur and Seqirus outside the submitted work. Dr. Peltan reports grants from Centers for Disease Control and Prevention, during the conduct of the study; grants from National Institutes of Health, grants from Janssen Pharmaceuticals, other from Asahi Kasei Pharma, other from Regeneron, outside the submitted work. Dr. Rice reports grants from Centers for Disease Control, during the conduct of the study; personal fees from Cumberland Pharmaceuticals, Inc, personal fees from Avisa Pharma, LLC, personal fees from Sanofi, outside the submitted work. Dr. Self reported research funding from CDC for the current project and consulting fees outside the submitted work from Aeprio Pharmaceuticals and Merck. The other authors reported no potential conflict of interest.Clinical TrialThis is an observational study and not an interventional trial.Funding StatementPrimary funding for this study was provided by the US Centers for Disease Control and Prevention (75D30121F00002). The REDCap data tool was supported by a Clinical and Translational Science Award (UL1 TR002243) from the National Center for Advancing Translational Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following two Institutional Review Boards provided ethical approval for this work as a public health surveillance program with research exemption: [1] Vanderbilt University Medical Center (Nashville, Tennessee, United States; protocol number: 210357; determination: non-research public health surveillance; date of determination: 22 February 2021); and [2] The United States Centers for Disease Control and Prevention (Atlanta, Georgia, United States; protocol number: 0900f3eb81c1be34; determination: non-research public health surveillance; date of determination: 26 February 2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this project are not available outside of the investigator group.